Literature DB >> 26751858

The influence of royal jelly and human interferon-alpha (HuIFN-αN3) on proliferation, glutathione level and lipid peroxidation in human colorectal adenocarcinoma cells in vitro.

Bratko Filipič, Lidija Gradišnik, Klemen Rihar, Eugen Šooš, Adriana Pereyra, Jana Potokar.   

Abstract

Among royal jelly's (RJ) various biological activities, its possible antitumour activity deserves particular attention. The purpose of this study was to investigate the influence of RJ, its bioactive component 10-hydroxy-2-decenoic acid (10- HDA), and human interferon-alpha (HuIFN-αN3) on the proliferation of human colorectal adenocarcinoma cells (CaCo- 2), and ascertain their effect on intracellular glutathione (GSH) level and lipid peroxidation. We studied the antiproliferative (AP) activity of RJ [(0.1 g/10 mL phosphate buffer saline (PBS)], HuIFN-αN3 (1000 I.U. mL⁻¹), 10-HDA at 100.0 μmol L⁻¹, and their different combinations, in the ratio 1:1, 1:2, and 2:1 on CaCo-2 cells. The GSH level was measured by glutathione assay. The lipid peroxidation was measured by malondialdehyde (MDA) assay. Single RJ had a low AP activity: 2.0 (0.5 mg mL⁻¹). HuIFN-αN3 had an AP activity of 2.5 (208.33 I.U. mL⁻¹), while 10-HDA had an AP activity of 1.5 (37.5 μmol mL⁻¹). The highest AP activity of 3.8 was obtained when RJ and HuIFN-αN3 were applied at the ratio 2:1. In that combination the level of GSH was 24.9±2.4 nmol g⁻³ of proteins (vs. 70.2±3.2 nmol g⁻³ in the control) and the level of MDA was 72.3±3.1 nmol g⁻³ (vs. 23.6±9.1 nmol g⁻³ in the control). It is generally assumed that 10-HDA, an important constituent of RJ, together with HuIFN-αN3, is responsible for the inhibition of CaCo-2 cells proliferation in vitro. In our study, however, RJ and HuIFN-αN3 applied at 2:1 decreased the level of GSH the most and significantly increased lipid peroxidation via MDA in CaCo-2 cells. Future studies should show whether these GSH- and MDA-related activities of RJ, HuIFN-αN3, 10-HDA, and their combinations may decrease the tumorigenicity index and tumorigenic potential of various tumour cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26751858     DOI: 10.1515/aiht-2015-66-2632

Source DB:  PubMed          Journal:  Arh Hig Rada Toksikol        ISSN: 0004-1254            Impact factor:   1.948


  10 in total

1.  Royal Jelly and trans-10-Hydroxy-2-Decenoic Acid Inhibit Migration and Invasion of Colorectal Carcinoma Cells.

Authors:  Milena M Jovanović; Dragana S Šeklić; Jelena D Rakobradović; Nevena S Planojević; Nenad L Vuković; Milena D Vukić; Snežana D Marković
Journal:  Food Technol Biotechnol       Date:  2022-06       Impact factor: 2.330

2.  10-Hydroxydec-2-Enoic Acid Reduces Hydroxyl Free Radical-Induced Damage to Vascular Smooth Muscle Cells by Rescuing Protein and Energy Metabolism.

Authors:  Pei Fan; Fangfang Sha; Chuan Ma; Qiaohong Wei; Yaqi Zhou; Jing Shi; Jiaojiao Fu; Lu Zhang; Bin Han; Jianke Li
Journal:  Front Nutr       Date:  2022-05-26

Review 3.  Health Promoting Properties of Bee Royal Jelly: Food of the Queens.

Authors:  Nicolas Collazo; Maria Carpena; Bernabe Nuñez-Estevez; Paz Otero; Jesus Simal-Gandara; Miguel A Prieto
Journal:  Nutrients       Date:  2021-02-07       Impact factor: 5.717

Review 4.  Antioxidant Potential of Propolis, Bee Pollen, and Royal Jelly: Possible Medical Application.

Authors:  Joanna Kocot; Małgorzata Kiełczykowska; Dorota Luchowska-Kocot; Jacek Kurzepa; Irena Musik
Journal:  Oxid Med Cell Longev       Date:  2018-05-02       Impact factor: 6.543

Review 5.  New Insights into the Biological and Pharmaceutical Properties of Royal Jelly.

Authors:  Saboor Ahmad; Maria Graça Campos; Filippo Fratini; Solomon Zewdu Altaye; Jianke Li
Journal:  Int J Mol Sci       Date:  2020-01-08       Impact factor: 5.923

6.  Anti-Tumor Effects of Queen Bee Acid (10-Hydroxy-2-Decenoic Acid) Alone and in Combination with Cyclophosphamide and Its Cellular Mechanisms against Ehrlich Solid Tumor in Mice.

Authors:  Aishah E Albalawi; Norah A Althobaiti; Salma Saleh Alrdahe; Reem Hasaballah Alhasani; Fatima S Alaryani; Mona Nasser BinMowyna
Journal:  Molecules       Date:  2021-11-20       Impact factor: 4.411

Review 7.  Royal Jelly: Beneficial Properties and Synergistic Effects with Chemotherapeutic Drugs with Particular Emphasis in Anticancer Strategies.

Authors:  Suzy Salama; Qiyang Shou; Aida A Abd El-Wahed; Nizar Elias; Jianbo Xiao; Ahmed Swillam; Muhammad Umair; Zhiming Guo; Maria Daglia; Kai Wang; Shaden A M Khalifa; Hesham R El-Seedi
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

8.  Thymoquinone anticancer activity is enhanced when combined with royal jelly in human breast cancer.

Authors:  Maya M Moubarak; Nour Chanouha; Najwa Abou Ibrahim; Hala Khalife; Hala Gali-Muhtasib
Journal:  World J Clin Oncol       Date:  2021-05-24

9.  Formulation of Ocular In Situ Gels with Lithuanian Royal Jelly and Their Biopharmaceutical Evaluation In Vitro.

Authors:  Kristina Perminaite; Mindaugas Marksa; Monika Stančiauskaitė; Tadas Juknius; Aidas Grigonis; Kristina Ramanauskiene
Journal:  Molecules       Date:  2021-06-10       Impact factor: 4.411

Review 10.  Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2018-10-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.